Yichen Zhong

782 total citations
31 papers, 583 citations indexed

About

Yichen Zhong is a scholar working on Oncology, Economics and Econometrics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yichen Zhong has authored 31 papers receiving a total of 583 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 8 papers in Economics and Econometrics and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yichen Zhong's work include Esophageal Cancer Research and Treatment (5 papers), Economic and Financial Impacts of Cancer (5 papers) and Bladder and Urothelial Cancer Treatments (5 papers). Yichen Zhong is often cited by papers focused on Esophageal Cancer Research and Treatment (5 papers), Economic and Financial Impacts of Cancer (5 papers) and Bladder and Urothelial Cancer Treatments (5 papers). Yichen Zhong collaborates with scholars based in United States, China and United Kingdom. Yichen Zhong's co-authors include Amy H. Auchincloss, Brian K. Lee, Genevieve P. Kanter, Jipan Xie, Mei Lü, Vanja Sikirica, Kavita Gajria, Haojie Li, James Signorovitch and Marisa A. Bittoni and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.

In The Last Decade

Yichen Zhong

27 papers receiving 577 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yichen Zhong United States	14	156	125	123	117	96	31	583
Leo Waterston United States	8	42 0.3×	118 0.9×	126 1.0×	58 0.5×	60 0.6×	14	452
Adam Lowy Switzerland	16	246 1.6×	76 0.6×	241 2.0×	32 0.3×	80 0.8×	20	874
Indra Tumur United Kingdom	11	40 0.3×	59 0.5×	90 0.7×	45 0.4×	178 1.9×	11	812
Janice Tzeng United States	15	45 0.3×	43 0.3×	126 1.0×	196 1.7×	70 0.7×	33	645
Ashley F. Slagle United States	8	78 0.5×	37 0.3×	59 0.5×	82 0.7×	113 1.2×	26	437
Vítor Rodrigues Portugal	14	59 0.4×	42 0.3×	135 1.1×	26 0.2×	18 0.2×	58	619
I. Gilloteau United States	18	70 0.4×	35 0.3×	200 1.6×	123 1.1×	172 1.8×	48	998
Margaret Barton‐Burke United States	13	25 0.2×	112 0.9×	325 2.6×	94 0.8×	18 0.2×	51	631
Cheryl D. Coon United States	10	41 0.3×	57 0.5×	154 1.3×	36 0.3×	93 1.0×	23	414
Philip Roe United Kingdom	7	52 0.3×	61 0.5×	74 0.6×	119 1.0×	29 0.3×	13	444

Countries citing papers authored by Yichen Zhong

Since Specialization

Citations

This map shows the geographic impact of Yichen Zhong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yichen Zhong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yichen Zhong more than expected).

Fields of papers citing papers by Yichen Zhong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yichen Zhong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yichen Zhong. The network helps show where Yichen Zhong may publish in the future.

Co-authorship network of co-authors of Yichen Zhong

This figure shows the co-authorship network connecting the top 25 collaborators of Yichen Zhong. A scholar is included among the top collaborators of Yichen Zhong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yichen Zhong. Yichen Zhong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gold, Linda Stein, Michael Sebastian, Brandon Becker, et al.. (2025). Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 (TYK2) Inhibitor, in Patients with Moderate to Severe Scalp Psoriasis: Time to Meaningful Improvement in Patient-Reported Outcomes in a Phase 3b/4, Multicenter, Randomized, Double-blinded, Placebo-Controlled Study (PSORIATYK SCALP). SKIN The Journal of Cutaneous Medicine. 9(2). s533–s533.

Zhong, Yichen, et al.. (2024). The Association Between Patient-Reported Disease Burden and Treatment Switching in Patients with Plaque Psoriasis Treated with Nonbiologic Systemic Therapy. PubMed. Volume 14. 167–174.

Zhong, Yichen, et al.. (2023). Multitask joint learning with graph autoencoders for predicting potential MiRNA-drug associations. Artificial Intelligence in Medicine. 145. 102665–102665. 2 indexed citations

Armstrong, April W., Richard B. Warren, Yichen Zhong, et al.. (2023). Short-, Mid-, and Long-Term Efficacy of Deucravacitinib Versus Biologics and Nonbiologics for Plaque Psoriasis: A Network Meta-Analysis. Dermatology and Therapy. 13(11). 2839–2857. 23 indexed citations

Qu, Tingting, et al.. (2022). Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer’s Perspective. PharmacoEconomics. 40(12). 1247–1259. 3 indexed citations

Zhong, Yichen, et al.. (2022). Improving the Prediction of Potential Kinase Inhibitors with Feature Learning on Multisource Knowledge. Interdisciplinary Sciences Computational Life Sciences. 14(3). 775–785. 2 indexed citations

Zhong, Yichen, Amy H. Auchincloss, Mark Stehr, & Brent A. Langellier. (2021). Are price discounts on sugar-sweetened beverages (SSB) linked to household SSB purchases? – a cross-sectional study in a large US household and retail scanner database. Nutrition Journal. 20(1). 29–29. 6 indexed citations

Wu, Huanhuan, et al.. (2021). Automatic diagnosis of COVID-19 infection based on ontology reasoning. BMC Medical Informatics and Decision Making. 21(S9). 271–271. 3 indexed citations

Zhong, Yichen, Haojie Li, Yang Meng, et al.. (2020). The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States. Journal of Medical Economics. 23(9). 967–977. 16 indexed citations

10.

Bensimon, Arielle G., Yichen Zhong, Umang Swami, et al.. (2020). Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma. Current Medical Research and Opinion. 36(9). 1507–1517. 18 indexed citations

11.

Bittoni, Marisa A., Ashwini Arunachalam, Haojie Li, et al.. (2018). Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With First-line Therapies for Medicare Patients 65 Years and Older With Advanced Non–small-cell Lung Cancer: A Retrospective Study. Clinical Lung Cancer. 19(5). e629–e645. 46 indexed citations

12.

Zhong, Yichen, Amy H. Auchincloss, Brian K. Lee, & Genevieve P. Kanter. (2018). The Short-Term Impacts of the Philadelphia Beverage Tax on Beverage Consumption. American Journal of Preventive Medicine. 55(1). 26–34. 101 indexed citations

13.

Prabhu, Vimalanand S., Haojie Li, Ruifeng Xu, et al.. (2018). Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden. European Urology Oncology. 3(5). 663–670. 15 indexed citations

14.

Arunachalam, Ashwini, Haojie Li, Marisa A. Bittoni, et al.. (2018). Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 19(5). e783–e799. 36 indexed citations

15.

Cao, Xiting, et al.. (2018). Survival Rates and Health Care Costs for Patients With Advanced Bladder Cancer Treated and Untreated With Chemotherapy. Clinical Genitourinary Cancer. 16(4). e909–e917. 14 indexed citations

16.

Li, Nanxin, Yanni Hao, Jipan Xie, et al.. (2015). Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer. Current Medical Research and Opinion. 31(8). 1573–1582. 4 indexed citations

17.

Lin, Peggy L., Yanni Hao, Jipan Xie, et al.. (2015). Physician experiences and preferences in the treatment of HR+/HER2− metastatic breast cancer in the United States: a physician survey. Cancer Medicine. 5(2). 209–220. 11 indexed citations

18.

Zhou, Zheng‐Yi, et al.. (2015). Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder. Journal of Medical Economics. 18(11). 919–929. 2 indexed citations

19.

Zhong, Yichen, Álvaro Muñoz, George J. Schwartz, et al.. (2014). Nonlinear Trajectory of GFR in Children before RRT. Journal of the American Society of Nephrology. 25(5). 913–917. 14 indexed citations

20.

Blaha, Michael J., Yichen Zhong, Seamus P. Whelton, et al.. (2013). Abstract 18564: The Interaction of Age and Exercise Capacity in the Prediction of All-Cause Mortality: Data From the FIT Project. Circulation. 128(suppl_22). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact